Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 2, 2015, Pages 371-376

  Shavit, E ^a,b   Dreiher, J ^b,c   Freud, T ^b   Halevy, S ^a,b   Vinker, S ^c,d   Cohen, A D ^b,c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c CLALIT HEALTH SERVICES   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CHILD; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SUPPURATIVE HIDRADENITIS; VERY ELDERLY; COMPLICATION; INFANT; MENTAL DISEASE; MIDDLE AGED; PRESCHOOL CHILD; PSYCHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; INFANT; MALE; MENTAL DISORDERS; MIDDLE AGED; YOUNG ADULT;

EID: 84921605140     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12567     Document Type: Article

References (32)

1. Jemec GBE, Revuz J, Leyden JJ, (eds). Hidradenitis suppurativa. Springer Verlag, Berlin, 2006.
2. Hurley HJ,. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In:, Roenigk RK, Roenigk HH Jr, eds. Dermatologic Surgery: Principles and Practice, 2nd edn. Marcel Dekker, New York, 1996: 623-645.
3. Sartorius K, Lapins J, Emtestam L, Jemec GB,. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003; 149: 211-213.
4. Von der Werth JM, Williams HC,. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000; 14: 389-392.
5. Jemec GB,. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366: 158-164.
6. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al,. Prevalence and factors associated with hidradenitis suppurativa. J Am Acad Dermatol 2008; 59: 596-601.
7. Jemec GB, Heidenheim M, Nielsen NH,. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-194.
8. Von Laffert M, Helmbold P, Wohlrab J, et al,. Hideradenitis suppurativa: early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19: 533-537.
9. Onderdijk AJ, Van der Zee HH, Esmann S, et al,. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013; 27: 473-478.
10. Vazquez BG, Alikhan A, Weaver AL, et al,. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013; 133: 97-103.
11. Matusiak L, Bieniek A, Szepietowski JC,. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010; 90: 264-268.
12. Rennert G, Peterburg Y,. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J 2001; 3: 404-408.
13. Cohen AD, Dreiher J, Shapiro Y, et al,. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 585-589.
14. Cohen AD, Sherf M, Vidavsky L, et al,. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155.
15. Cohen AD, Weitzman D, Dreiher J,. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010; 90: 23-26.
16. Dreiher J, Weitzman D, Davidovici B, et al,. Psoriasis and dyslipidemia: a population-based study. Acta Derm Venereol 2008; 88: 561-565.
17. Dreiher J, Weitzman D, Shapiro J, et al,. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol 2008; 159: 956-960.
18. Wohl Y, Dreiher J, Cohen AD,. Pemphigus and dyslipidemia: a case-control study. Br J Dermatol 2009; 161: 1418-1420.
19. Dreiher J, Shapiro J, Cohen AD,. Lichen planus and dyslipidemia: a case-control study. Br J Dermatol 2009; 161: 626-629.
20. Hodak E, Lessin S, Friedland R, et al,. New insight into associated co-morbididities in patients with cutaneous T-cell Lymphoma (Mycosis fungoides). Acta Derm Venereol 2013; 93: 451-454.
21. Bayers AL, Yaffe K, Covinsky KE, et al,. High occurrence of mood and anxiety disorders among older adults. Arch Gen Psychiatry 2010; 67: 489-496.
22. Bögels SM, Alden L, Beidel DC, et al,. Social anxiety disorder: questions and answers for the DSM-V. Depress Anxiety 2010; 27: 168-189.
23. Kessler RC, Berglund P, Demler O, et al,. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
24. Gupta AK, Knowles SR, Gupta MA, et al,. Lithium therapy associated with hidradenitis suppurativa. J Am Acad Dermatol 1995; 32: 382-386.
25. Marinella MA,. Lithium therapy associated with hidradenitis suppurativa. Acta Dern Venereol 1997; 77: 483.
26. Cosmatos I, Matcho A, Weinstein R, et al,. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2013; 68: 412-419.
27. Kraft JN, Searles GE,. Hidradenitis suppurativa in female patients. J Cutan Med Surg 2007; 11: 125-131.
28. Van der Zee HH, de Ruiter L, van den Broecke DG, et al,. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-1298.
29. Matusiak L, Bieniek A, Szepietowski JC,. Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging. Biomarkers 2009; 14: 432-437.
30. Lee SY, Chen SL, Chang YH, et al,. Inflammation's association with metabolic profiles before and after a twelve-week clinical trial drug-naïve patients with bipolar II disorder. PLoS ONE 2013; 8: e66847.
31. Henje BE, Lekander M, Ingvar M, et al,. Pro-inflammatory cytokines are elevated in adolescent females with emotional disorders not treated with SSRI's. J Affect Disord 2012; 136: 716-723.
32. De Souza DF, Wartchow K, Hansen F, et al,. Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2013; 43: 14-22.